Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioInvent International AB ( (SE:BINV) ) has provided an announcement.
BioInvent International AB will host a virtual key opinion leader event on May 27, 2026, to spotlight its anti-TNFR2 antibody BI-1808 for ovarian cancer, featuring oncologist Dmitriy Zamarin and company executives. The webcast will review the ovarian cancer treatment landscape, BI-1808’s differentiated mechanism of action, translational data, and the market opportunity, positioning the company as it seeks to capitalize on promising early clinical signals.
The company will highlight interim data showing BI-1808 plus pembrolizumab delivered an overall response rate roughly three times higher than historical figures for pembrolizumab alone in heavily pretreated ovarian cancer patients. The event, first in a two-part KOL series that also covers BI-1206 and BI-1808 in lymphomas, underscores BioInvent’s bid to strengthen its profile in cancer immunotherapy and could influence investor perception as the BI-1808 Phase 2a program advances.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotechnology company based in Lund, Sweden, focused on discovering and developing first-in-class immuno-modulatory antibodies for cancer therapy. The company’s pipeline includes drug candidates such as BI-1808 and BI-1206, targeting tumor-associated regulatory T cells and other immune pathways in solid tumors and T-cell lymphomas.
Average Trading Volume: 121,117
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.5B
For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.